The combination of circumstances confronting the sector must be unprecedented - 20 per cent growth in spending on the PBS, but actually no growth, a policy requirement to offset the cost of all new listings driven by impossible fiscal circumstances, with an existing $2 billion hole in health spending, against the backdrop of the Turnbull government's innovation agenda and commitment to fund new medicines. What does it all mean?
Latest Video
New Stories
-
AbbVie records a 13-year streak as 'A Great Place to Work'
July 29, 2026 - - Latest News -
Helping to build Australia’s life sciences future at Brisbane’s innovation junction
July 29, 2026 - - Latest News -
AFT Pharmaceuticals sees significant opportunity in a diverse R&D pipeline
July 28, 2026 - - Latest News -
New research shows chronic pain is widespread and undertreated in Australia
July 28, 2026 - - Latest News -
Long-COVID still reshaping life for medically vulnerable Australians
July 28, 2026 - - Latest News -
Australians with rare diseases still waiting too long for access to treatments
July 28, 2026 - - Latest News -
TGA approves GSK's six‑monthly treatment for severe eosinophilic asthma and nasal polyps
July 28, 2026 - - Latest News

